Tilray is accelerating its operations in Europe thanks to a license in Portugal

Tilray Medical has obtained a new license in Portugal, allowing the company to conduct quality tests on medical cannabis directly at its facility in Cantanhede, in the central part of the country. This decision is expected to speed up the time to market for products processed at its facility, reduce operating costs, and strengthen the company’s position in the European market.

Announced on October 13, 2026, this authorization was issued by INFARMED, the Portuguese National Authority for Medicines and Health Products. It covers the microbiological and physicochemical tests conducted at Tilray's EU-GMP facility. These tests are part of the pharmaceutical quality control measures required for bringing cannabis-based medical products to market.

Bringing cannabis quality control under one roof

Until now, Tilray has relied in part on external laboratories to conduct these tests. This change is expected to shorten the time between the harvest, quality control, and distribution. It could also reduce expenses related to third-party laboratories while giving Tilray greater control over its production schedule.

Microbiological testing helps identify potential contamination, while physicochemical analyses help verify the characteristics of the products and their compliance with applicable pharmaceutical standards.

For companies that supply multiple countries, these procedures are an essential step before products can be placed on the market.

Portugal, a Strategic Hub

This authorization further strengthens Portugal’s role within Tilray’s international production network. Its Cantanhede facility already combines cannabis cultivation, processing, and pharmaceutical manufacturing. The addition of in-house laboratory capabilities makes this facility a more integrated platform for supplying regulated international markets.

Rajnish Ohri, president of international operations at Tilray Brands, described this development as an important step in the company’s expansion strategy:

«As regulated medical cannabis markets continue to mature, the companies best positioned to lead will be those that combine pharmaceutical-grade quality, regulatory rigor, and a reliable, large-scale global supply chain. Tilray has established one of the world’s leading EU-GMP-certified medical cannabis operations, and this authorization further strengthens our platform in Portugal by bringing advanced quality testing closer to cultivation and production. It gives us greater speed, control, and flexibility throughout our international supply chain, while strengthening the infrastructure and technical expertise needed to provide patients, physicians, pharmacies, and business partners with reliable medical cannabis products in highly regulated markets around the world. »

The company cites Germany, the United Kingdom, Poland and Italy among the markets served by its international supply chain. Tilray has also expanded the availability of its branded medical cannabis products in the United Kingdom through Lyphe Clinic and Lyphe Dispensary.

A context of mixed financial results

Tilray is facing mixed financial trends. For the quarter ended August 31, 2026, the company’s net cannabis revenue declined to $56.1 million, compared with $64.5 million in the same period a year earlier.

Its gross margin from cannabis improved, rising from 36 to 39%, suggesting improved profitability in the segment despite declining sales.

Across its diverse range of businesses, including beverages, wellness, and pharmaceutical distribution, total quarterly revenue rose from $209.5 million to $257.1 million.